Effect of OM-85 BV on reducing bronchiectasis exacerbation in Chinese patients: the iPROBE study.

ABSTRACT:

Background

Bronchiectasis is characterized by recurrent infectious exacerbations. No existing data inform preventive strategy for exacerbations beyond chronic macrolides. OM-85 BV, an immunostimulant, has been shown to prevent recurrent respiratory infections. We initiated this 1-year, multi-centered, double-blind, and controlled trial to investigate the PReventive effect of OM-85 BV on Bronchiectasis Exacerbations in Chinese patients (iPROBE).

Methods

Patients with bronchiectasis aged 18 to 75 years, having at least one exacerbation in the past year, were randomized to receive, in addition to any respiratory medications, two courses of 7 mg of OM-85 BV or matching placebo (one capsule orally per day for 10 days a month) for 3 consecutive months, followed by 3 months without

SUBMITTER: Gao J 

PROVIDER: S-EPMC8024857 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature